Coronavirus (892) Weekly update no.18 - Evidence Aid COVID-19 project

13 August, 2020

Dear Friends (with apologies for any cross-posting),

If you are passing this update to friends or colleagues and they would like to subscribe to these weekly updates (or if you would like to un-subscribe), please contact Ben Heaven Taylor (

Here is the 18th weekly update on Evidence Aid’s COVID-19 project.

Highlights: The number of users on the website has now exceeded 240,000.

Evidence Aid COVID-19 Weekly Bulletin

Report covering 7 days to 11th August 2020 -

Systematic review summaries

382 summaries on the website in total (7 added in this period); 90 summaries in progress;


370 in Arabic; 370 in Chinese (simplified); 370 in Chinese (traditional); 369 in French; 47 in Italian; 368 in Portuguese; 366 in Spanish;

Literature searches

0 search completed in this period; 0 search in progress; 488 records were screened


A total of 63 amazing volunteers (39 summary writers; 10 screeners; 15 information specialists/librarians) from 15 countries;

Digital engagement

25,946 people have used the Evidence website in this 7-day period for a total of 241,154 users since we started collecting data in mid-March. Our top ten countries this week were: Mexico, Argentina, Chile, Egypt, El Salvador, Iraq, Bolivia, Algeria, USA, Brazil.

The summaries with most views this week were D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis (in Arabic) N95 respirators and surgical masks for preventing transmission of respiratory infections to healthcare workers, (in Spanish) and Rehabilitation and early mobilisation in the critical patient (in Spanish).


We are grateful to Twitter, who have granted us substantial pro-bono advertising. Among others, we are collaborating with WHO, Public Health England, PAHO, Queen’s University Belfast, Health and Social Care Northern Ireland, Cochrane, Campbell, Translators Without Borders, Global Evidence Synthesis Initiative, the Irish Global Health Network, Health Service Executive Ireland, McMaster University (COVID-END) and Oxford PharmaGenesis. Evidence Aid are supported by H2H, with funding from UK Aid, and by a core grant from Oxford PharmaGenesis. As a direct result of presenting our work to Oxford Pharmagenesis recently, we had several additional volunteers come forward.

Best wishes,


Ben Heaven Taylor

Chief Executive Officer

Email: | skype: live:ben_taylor45 |Phone: +44 (0)7880 635014 |Web: | Twitter @EvidenceAid

Championing evidence-based humanitarian action

Support our activities by donating here.

For the Evidence Aid resources on COVID-19 (Coronavirus), visit